Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Wisconsin-Madison
Headquarters: Madison, WI, United States of America
Website: http://www.wisc.edu
Year Founded: 1848
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Sep 21, 2023
Emerging Company Profile
hC Bio: restoring protein function with tRNA therapies
Its sights set on cancer and rare diseases, Boston-based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year
BioCentury | Apr 20, 2023
Discovery & Translation
CRISPR guide RNAs with guardrails, bacterial sensors for pathogen detection and more
BioCentury’s roundup of translational news
BioCentury | Jan 25, 2023
Emerging Company Profile
Fauna Bio: finding human drug targets using animal omics data
Bay Area biotech is taking a comparative genomics approach, starting with biobank data from the thirteen-lined ground squirrel
BioCentury | Jun 16, 2021
Deals
Castration-resistant prostate cancer deals continue to trickle: Data Byte
Deal activity in castration-resistant prostate cancer (CRPC) continues to be quiet this year, with two clinical partnerships disclosed so far. Both of the deals involved combination trials with
BioCentury | Apr 29, 2020
Product Development
India emerging as major COVID-19 vaccine manufacturer
Serum Institute of India plans to make low-cost COVID-19 vaccines available to the developing world
BioCentury | Mar 21, 2020
Finance
Design debuts with $45M series A, portfolio against repeat expansions
BioCentury | Jun 7, 2019
Translation in Brief
Binding the extracellular matrix to target brain tissue
Binding the extracellular matrix exposed by disrupted BBB to target brain tissue
BioCentury | Jun 4, 2019
Distillery Therapeutics
Targeting brain extracellular matrix to improve doxorubicin efficacy in GBM
Items per page:
1 - 10 of 127